Physician profile
Aurora C Andreescu
NPI 1912047754
$1,833.34
in general payments reported to CMS, 2019-2025
14 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.59 · 2020: $139 · 2021: $118 · 2022: $163 · 2023: $438 · 2024: $262 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.68 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.39 | 2020-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $420.24 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $181.08 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $173.14 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.77 | 2023 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $49.17 | 2024-2025 | Contrave |
| Amgen INC. | $37.11 | 2024-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $28.62 | 2019-2023 | |
| Abbott Laboratories | $19.80 | 2021 | |
| Pfizer INC. | $14.91 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.77 | 2021 | |
| Merck Sharp & Dohme LLC | $12.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Andreescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.